✦ LIBER ✦

Polymorphisms in the promoter region of theCASP8gene are not associated with non-Hodgkin’s lymphoma in Chinese patients

✍ Scribed by Mei-Sheng Xiao; Deng-Feng Zhang; Yun Zeng; Yun-Feng Cheng; Yong-Gang Yao

Publisher: Springer
Year: 2011
Tongue: English
Weight: 1010 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1265-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HHV8-related non-Hodgkin's lymphoma of t

✍ Emmanuelle Boulanger; Josette Briere; Philippe Gaulard; Dominique Droz; Eric Oks 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

In a recent report, we described the features of 14 cases of Kaposi sarcoma-associated herpesvirus (HHV8/KSHV)-related non-Hodgkin's lymphoma (NHL) occurring during the follow-up of 60 HIVinfected patients with multicentric Castleman disease (MCD) [1]. Herein we report a new case of NHL arising in t

The interferon-γ receptor gene polymorph

The interferon-γ receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients

✍ Xu Yao; Zhi-Qiang Chen; Juan-Qin Gong; Min Chen; An-Sheng Li; Jun Liu 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 262 KB

Two polymorphisms of presenilin-2 gene (

Two polymorphisms of presenilin-2 gene (PSEN2) 5′ regulatory region are not associated with Alzheimer’s disease (AD) in the Polish population

✍ M. Gacia; K. Safranow; T. Gabryelewicz; M. Styczyńska; B. Pepłońska; V. Dziedzie 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 81 KB

Prognostic factors of Chinese patients w

Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin’s lymphoma: the single-institute experience in Taiwan

✍ Yu-Hui Hu; Liang-Tsai Hsiao; Ching-Fen Yang; Tzeon-Jye Chiou; Jin-Hwang Liu; Jyh 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 148 KB

Genetic polymorphisms in the promoter an

Genetic polymorphisms in the promoter and 5′ UTR region of the Fc α receptor (CD89) are not associated with a risk of IgA nephropathy

✍ I. Narita; S. Goto; N. Saito; M. Sakatsume; S. Jin; K. Omori; F. Gejyo 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 65 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa